Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Pediatric Endocrinology
Published in: International Journal of Pediatric Endocrinology 1/2013

Open Access 01-12-2013 | Review

Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management

Authors: Katherine Lord, Diva D De León

Published in: International Journal of Pediatric Endocrinology | Issue 1/2013

Login to get access

Abstract

Hyperinsulinism (HI) is the leading cause of persistent hypoglycemia in children,which if unrecognized may lead to development delays and permanent neurologicdamage. Prompt recognition and appropriate treatment of HI are essential toavoid these sequelae. Major advances have been made over the past two decades inunderstanding the molecular basis of hyperinsulinism and mutations in nine genesare currently known to cause HI. Inactivating KATP channel mutationscause the most common and severe type of HI, which occurs in both a focal and adiffuse form. Activating mutations of glutamate dehydrogenase (GDH) lead tohyperinsulinism/hyperammonemia syndrome, while activating mutations ofglucokinase (GK), the “glucose sensor” of the beta cell, causeshyperinsulinism with a variable clinical phenotype. More recently identifiedgenetic causes include mutations in the genes encoding short-chain3-hydroxyacyl-CoA (SCHAD), uncoupling protein 2 (UCP2), hepatocyte nuclearfactor 4-alpha (HNF-4α), hepatocyte nuclear factor 1-alpha (HNF-1α),and monocarboyxlate transporter 1 (MCT-1), which results in a very rare form ofHI triggered by exercise. For a timely diagnosis, a critical sample and aglucagon stimulation test should be done when plasma glucose is < 50 mg/dL.A failure to respond to a trial of diazoxide, a KATP channel agonist,suggests a KATP defect, which frequently requires pancreatectomy.Surgery is palliative for children with diffuse KATPHI, but childrenwith focal KATPHI are cured with a limited pancreatectomy. Therefore,distinguishing between diffuse and focal disease and localizing the focal lesionin the pancreas are crucial aspects of HI management. Since 2003,18 F-DOPA PET scans have been used to differentiate diffuse andfocal disease and localize focal lesions with higher sensitivity and specificitythan more invasive interventional radiology techniques. Hyperinsulinism remainsa challenging disorder, but recent advances in the understanding of its geneticbasis and breakthroughs in management should lead to improved outcomes for thesechildren.
Appendix
Available only for authorised users
Literature
1.
Mazor-Aronovitch K, Gillis D, Lobel D, Hirsch HJ, Pinhas-Hamiel O, Modan-Moses D, Glaser B, Landau H: Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism. Eur J Endocrinol 2007, 157(4):491–497.CrossRefPubMed
2.
Stanley CA, De Leon DD: Monogenic Hyperinsulinemic Hypoglycemia Disorders. 1st edition. Basel: Karger; 2012.CrossRef
3.
Monogenic Disorders of Insulin Secretion: Congenital Hyperinsulinism and Neonatal Diabetes March 15–16, 2012 Faculty Synopses. Pediatr Diabetes 2012, 13(4):344–368.CrossRef
4.
Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 1996, 5(11):1809–1812.CrossRefPubMed
5.
Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995, 268(5209):426–429.CrossRefPubMed
6.
Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko HL, Rahier J, Vauhkonen I, Kere J, Laakso M, Ashcroft F, et al: Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest 2000, 106(7):897–906.CrossRefPubMedPubMedCentral
7.
Pinney SE, MacMullen C, Becker SA, Lin YW, Hanna C, Thornton PS, Ganguly A, Shyng SL, Stanley CA: Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest 2008, 118(8):2877–2886.CrossRefPubMedPubMedCentral
8.
Macmullen CM, Zhou Q, Snider KE, Tewson PH, Becker SA, Aziz AR, Ganguly A, Shyng SL, Stanley CA: Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the beta-cell sulfonylurea receptor SUR1. Diabetes 2011, 60(6):1797–1804.CrossRefPubMedPubMedCentral
9.
De Leon DD, Stanley CA: Pathophysiology of Diffuse ATP-Sensitive Potassium Channel Hyperinsulinism. In Monogenic Hyperinsulinemic Hypoglycemia Disorders. 21st edition. Edited by De Leon DD, Stanley CA. Basel: Karger; 2012:18–29.CrossRef
10.
Fourtner SH, Stanley CA, Kelly A: Protein-sensitive hypoglycemia without leucine sensitivity in hyperinsulinism caused by K(ATP) channel mutations. J Pediatr 2006, 149(1):47–52.CrossRefPubMed
11.
Rahier J, Falt K, Muntefering H, Becker K, Gepts W, Falkmer S: The basic structural lesion of persistent neonatal hypoglycaemia with hyperinsulinism: deficiency of pancreatic D cells or hyperactivity of B cells? Diabetologia 1984, 26(4):282–289.CrossRefPubMed
12.
De Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, Bonnefont JP, Brusset MC, Brunelle F, Robert JJ, et al: Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 1997, 100(4):802–807.CrossRefPubMedPubMedCentral
13.
Verkarre V, Fournet JC, De Lonlay P, Gross-Morand MS, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, et al: Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 1998, 102(7):1286–1291.CrossRefPubMedPubMedCentral
14.
Suchi M, MacMullen CM, Thornton PS, Adzick NS, Ganguly A, Ruchelli ED, Stanley CA: Molecular and immunohistochemical analyses of the focal form of congenital hyperinsulinism. Mod Pathol 2006, 19(1):122–129.CrossRefPubMed
15.
Sempoux C, Capito C, Bellanne-Chantelot C, Verkarre V, De Lonlay P, Aigrain Y, Fekete C, Guiot Y, Rahier J: Morphological Mosaicism of the Pancreatic Islets: A Novel Anatomopathological Form of Persistent Hyperinsulinemic Hypoglycemia of Infancy. J Clin Endocrinol Metab 2011, 96(12):3785–3793.CrossRefPubMed
16.
Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998, 338(19):1352–1357.CrossRefPubMed
17.
Palladino AA, Stanley CA: The hyperinsulinism/hyperammonemia syndrome. Rev Endocr Metab Disord 2010, 11(3):171–178.CrossRefPubMed
18.
Bahi-Buisson N, Roze E, Dionisi C, Escande F, Valayannopoulos V, Feillet F, Heinrichs C: Neurological aspects of hyperinsulinism-hyperammonaemia syndrome. Dev Med Child Neurol 2008, 50(12):945–949.CrossRefPubMed
19.
Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, et al: Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998, 338(4):226–230.CrossRefPubMed
20.
Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, Suchi M, Taub R, Grimsby J, Matschinsky FM, et al: Extremes of Clinical and Enzymatic Phenotypes in Children With Hyperinsulinism Caused by Glucokinase Activating Mutations. Diabetes 2009, 58(6):1419–1427.CrossRefPubMedPubMedCentral
21.
Clayton PT: Hyperinsulinism in short-chain l-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. J Clin Invest 2001, 108(3):457–465.CrossRefPubMedPubMedCentral
22.
Li C, Chen P, Palladino A, Narayan S, Russell LK, Sayed S, Xiong G, Chen J, Stokes D, Butt YM: Mechanism of hyperinsulinism in short-chain 3- hydroxyacyl-CoA dehydrogenase deficiency involves activation of glutamate dehydrogenase. J Biol Chem 2010, 285(41):31806–31818.CrossRefPubMedPubMedCentral
23.
Gonzalez-Barroso MM, Giurgea I, Bouillaud F, Anedda A, Bellanne-Chantelot C, Hubert L, de Keyzer Y, de Lonlay P, Ricquier D: Mutations in UCP2 in Congenital Hyperinsulinism Reveal a Role for Regulation of Insulin Secretion. PLoS One 2008, 3(12):e3850.CrossRefPubMedPubMedCentral
24.
Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, Fajans SS, Signorini S, Stoffel M, Bell GI: Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996, 384(6608):458–460.CrossRefPubMed
25.
Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, Ellard S, Ferrer J, Hattersley AT: Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene. PLoS Med 2007, 4(4):e118.CrossRefPubMedPubMedCentral
26.
Flanagan SE, Kapoor RR, Mali G, Cody D, Murphy N, Schwahn B, Siahanidou T, Banerjee I, Akcay T, Rubio-Cabezas O, et al: Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol 2010, 162(5):987–992.CrossRefPubMedPubMedCentral
27.
Kapoor RR, Locke J, Colclough K, Wales J, Conn JJ, Hattersley AT, Ellard S, Hussain K: Persistent Hyperinsulinemic Hypoglycemia and Maturity-Onset Diabetes of the Young Due to Heterozygous HNF4A Mutations. Diabetes 2008, 57(6):1659–1663.CrossRefPubMed
28.
Stanescu DE, Hughes N, Kaplan B, Stanley CA, De Leon DD: Novel Presentations of Congenital Hyperinsulinism due to Mutations in the MODY genes: HNF1A and HNF4A. J Clin Endocrinol Metab 2012, 97(10):E2026–E2030.CrossRefPubMedPubMedCentral
29.
Meissner T, Otonkoski T, Feneberg R, Beinbrech B, Apostolidou S, Sipila I, Schaefer F, Mayatepek E: Exercise induced hypoglycaemic hyperinsulinism. Arch Dis Child 2001, 84(3):254–257.CrossRefPubMedPubMedCentral
30.
Otonkoski T, Jiao H, Kaminen-Ahola N, Tapia-Paez I, Ullah MS, Parton LE, Schuit F, Quintens R, Sipila I, Mayatepek E, et al: Physical Exercise.Induced Hypoglycemia Caused by Failed Silencing of Monocarboxylate Transporter 1 in Pancreatic β Cells. Am J Hum Genet 2007, 81(3):467–474.CrossRefPubMedPubMedCentral
31.
Otonkoski T, Kaminen N, Ustinov J, Lapatto R, Meissner T, Mayatepek E, Kere J, Sipila I: Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release. Diabetes 2003, 52(1):199–204.CrossRefPubMed
32.
Palladino AA, Bennett MJ, Stanley CA: Hyperinsulinism in Infancy and Childhood: When an Insulin Level Is Not Always Enough. Clin Chem 2008, 54(2):256–263.CrossRefPubMed
33.
Finegold DN, Stanley CA, Baker L: Glycemic response to glucagon during fasting hypoglycemia: an aid in the diagnosis of hyperinsulinism. J Pediatr 1980, 96(2):257–259.CrossRefPubMed
34.
Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJL, et al: An Activating Mutation of AKT2 and Human Hypoglycemia. Science 2011, 334(6055):474.CrossRefPubMedPubMedCentral
35.
Kelly A, Tang R, Becker S, Stanley CA: Poor Specificity of Low Growth Hormone and Cortisol Levels During Fasting Hypoglycemia for the Diagnoses of Growth Hormone Deficiency and Adrenal Insufficiency. Pediatrics 2008, 122(3):e522–e528.CrossRefPubMed
36.
Drash A, Wolff F: Drug Therapy in Leucine-Sensitive Hypoglycemia. Metab 1964, 13:487–492.CrossRef
37.
Hirsch HJ, Loo S, Evans N, Crigler JF, Filler RM, Gabbay KH: Hypoglycemia of infancy and nesidioblastosis. Studies with somatostatin. N Engl J Med 1977, 296(23):1323–1326.CrossRefPubMed
38.
Dayton PG, Pruitt AW, Faraj BA, Israili ZH: Metabolism and disposition of diazoxide. A mini-review. Drug Metab Dispos 1975, 3(3):226–229.PubMed
39.
Laje P, Halaby L, Adzick NS, Stanley CA: Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010, 11(2):142–147.CrossRefPubMed
40.
Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas-Hamiel O, Landau H: Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab 2011, 96(8):2312–2317.CrossRefPubMed
41.
Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanné-Chantelot C, Valayannopoulos V, Brassier A, Kayirangwa H, Barbier V, Broissand C, et al: Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012, 166(2):333–339.CrossRefPubMed
42.
Mohnike K, Blankenstein O, Pfuetzner A, Potzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM: Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 2008, 70(1):59–64.CrossRefPubMed
43.
Mazor-Aronovitch K, Landau H, Gillis D: Surgical versus non-surgical treatment of congenital hyperinsulinism. Pediatr Endocrinol Rev 2009, 6(3):424–430.PubMed
44.
Calabria AC, Li C, Gallagher PR, Stanley CA, De Leon DD: GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATPsensitive K+ channel. Diabetes 2012, 61(10):2585–2591.CrossRefPubMedPubMedCentral
45.
Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R, Zhuang H, MacMullen C, Becker S, Adzick NS, et al: Accuracy of [18 F]Fluorodopa Positron Emission Tomography for Diagnosing and Localizing Focal Congenital Hyperinsulinism. J Clin Endocrinol Metab 2007, 92(12):4706–4711.CrossRefPubMed
46.
Stanley CA, Thornton PS, Ganguly A, MacMullen C, Underwood P, Bhatia P, Steinkrauss L, Wanner L, Kaye R, Ruchelli E, et al: Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic arterial calcium stimulation. J Clin Endocrinol Metab 2004, 89(1):288–296.CrossRefPubMed
47.
Otonkoski T, Nanto-Salonen K, Seppanen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekstrom K, et al: Noninvasive diagnosis of focal hyperinsulinism of infancy with [18 F]-DOPA positron emission tomography. Diabetes 2006, 55(1):13–18.CrossRefPubMed
48.
Ribeiro M-J, de Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, Dolle F, Nihoul-Fekete C, Syrota A, Brunelle F: Characterization of hyperinsulinism in infancy assessed with PET and 18 F-fluoro-L-DOPA. J Nucl Med 2005, 46(4):560–566.PubMed
49.
Zani A, Nah SA, Ron O, Totonelli G, Ismail D, Smith VV, Ashworth M, Blankenstein O, Mohnike W, De Coppi P, et al: The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. J Pediatr Surg 2011, 46(1):204–208.CrossRefPubMed
50.
Blomberg BA, Moghbel MC, Saboury B, Stanley CA, Alavi A: The Value of Radiologic Interventions and (18)F-DOPA PET in Diagnosing and Localizing Focal Congenital Hyperinsulinism: Systematic Review and Meta-Analysis. Mol Imaging Biol 2013, 15(1):97–105.CrossRefPubMed
51.
Palladino AA, Stanley CA: A specialized team approach to diagnosis and medical versus surgical treatment of infants with congenital hyperinsulinism. Semin Pediatr Surg 2011, 20(1):32–37.CrossRefPubMed
52.
Lovvorn HN III, Nance ML, Ferry RJ Jr, Stolte L, Baker L, O'Neill JA Jr, Schnaufer L, Stanley CA, Adzick NS: Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. J Pediatr Surg 1999, 34(5):786–792. discussion 792-783.CrossRefPubMed
53.
Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J, Brunelle F, Nihoul-Fekete C, Saudubray JM, et al: Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012, 35(2):198–203.CrossRefPubMedPubMedCentral
Metadata
Title
Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
Authors
Katherine Lord
Diva D De León
Publication date
01-12-2013
Publisher
BioMed Central
Published in
International Journal of Pediatric Endocrinology / Issue 1/2013
Electronic ISSN: 1687-9856
DOI
https://doi.org/10.1186/1687-9856-2013-3

Other articles of this Issue 1/2013

International Journal of Pediatric Endocrinology 1/2013 Go to the issue

Research

Factors associated with low bone density in patients referred for assessment of bone health

PES Review

Endocrine manifestations and management of Prader-Willi syndrome

Research

Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS)

Research

Effect of the parental origin of the X-chromosome on the clinical features, associated complications, the two-year-response to growth hormone (rhGH) and the biochemical profile in patients with turner syndrome

Research

Congenital hypothyroidism after assisted reproductive technology in Japan: comparison between multiples and singletons, 2005–2009

Research

Children’s and adolescent’s self - assessment of metabolic control versus professional judgment: a cross-sectional retrospective and prospective cohort study